On June 26, 2026, the 2026 China Pharmaceutical Innovation 100 Conference themed “The Global Journey of the Top 100 Innovators” was held in Tianjin. This conference was guided by the Pharmaceutical and Health Industry Promotion Bureau of Tianjin Economic-Technological Development Area, and jointly hosted by Health Care Ｅxecutive and Asymchem Laboratories Group. At the conference, the ranking list of “2026 Top 100 China Pharmaceutical Innovation Enterprises” was officially unveiled. Biokin Pharmaceutical was once again named to the list on the strength of its sustained innovation capabilities.

       The “Top 100 China Pharmaceutical Innovation Enterprises” list has been released for eight consecutive years and is one of the pharmaceutical innovation selections with leading credibility and industry influence in China. The list is compiled by Health Care Ｅxecutive based on Clarivate Cortellis competitive intelligence and clinical trial data, as well as Derwent Innovation patent data. The evaluation covers three dimensions: innovation foundation, innovation process and innovation achievements. It comprehensively assesses enterprises’ innovation capability through four core indicators, including the core patent grant volume of innovative drugs, the peripheral patent grant volume of innovative drugs, the clinical trial count and the number of approved and marketed innovative drugs. Finally, the top 100 enterprises representing China’s pharmaceutical innovation strength are selected.